BioTuesdays

Category - Markets

Adamas Pharmaceuticals Logo
Markets

WB ups Adamas Pharma price target to $42

William Blair has raised its price target on Adamas Pharmaceuticals (NASDAQ:ADMS) to $42 from $35 after the company announced positive top-line results from its Phase 3 EASE LID trial with lead candidate ADS-5102...

December 23, 2015
fibrocell
Markets

Roth starts Fibrocell Science at buy

Roth Capital Partners has initiated coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and 12-month target price of $14. The stock closed at $5.28 on Monday. “Leaning on 20 years of experience with...

December 22, 2015
Relypsa
Markets

HCW starts Relypsa at buy

H.C. Wainwright has initiated coverage of Relypsa (NASDAQ:RLYP) with a “buy” rating and price target of $63. The stock closed at $28.31 on Wednesday. “We believe [Relypsa’s] Veltassa is well positioned to address the...

December 17, 2015
OraSure Technologies
Markets

BTIG starts OraSure Technologies at buy

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...

December 14, 2015
Piper Jaffray
Markets

Piper Jaffray top healthcare picks for 2016

Each year, Piper Jaffray asks its analysts to provide the one name in their universe where they believe they have a differentiated opinion, high conviction and see catalysts ahead in the coming year.Piper Jaffray’s Top...

December 10, 2015
Titan Pharmaceuticals Logo
Markets

Roth ups Titan Pharma price target to $7.25

Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed at $4.92 on...

December 4, 2015
Can-Fite
Markets

HCW ups Can-Fite BioPharma price target to $6

H.C. Wainwright has raised its price target on “buy-rated” Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) to $6 from $4. The stock closed at $3.23 on Friday. “In our view, the company’s piclidenoson programs remain the...

November 30, 2015
GW Pharmaceuticals
Markets

Roth reinitiates coverage of GW Pharma at buy

Roth Capital Partners is reinitiating coverage of GW Pharmaceuticals (NASDAQ:GWPH) with a “buy” rating and 12-month target price of $130 per American Depository Share. The ADS closed at $84.90 on Friday GW is developing...

November 30, 2015
Stellar Biotechnologies
Markets

Maxim starts Stellar Biotechnologies at buy

Maxim Group has initiated coverage of Stellar Biotechnologies (NASDAQ:SBOT) with a “buy” rating and $17 price target. The stock closed at $7.48 on Monday. Stellar leverages its on-land aquaculture facilities to...

November 24, 2015
MAST Therapeutics
Markets

Maxim starts Mast Therapeutics at buy

Maxim Group has initiated coverage of Mast Therapeutics (NYSE:MSTX) with a “buy” rating and price target of $5. The stock closed at 42 cents on Wednesday. Mast’s vepoloxamer is in the pivotal Phase 3 EPIC study, with...

November 12, 2015